<DOC>
	<DOCNO>NCT02102152</DOCNO>
	<brief_summary>The use inhaled medication treatment pulmonary disease allow delivery high concentration drug site disease reduce systemic absorption risk systemic adverse effect . Inhaled Tobramycin successfully use maintenance treatment CF patient chronic colonization PA ( Pseudomonas aeruginosa ) . In CF population TOBI proven improve lung function , decrease density PA sputum , decrease hospitalization , reduce risk mortality . Non CF Bronchiectasis share many feature common CF , include frequent colonization PA lead deterioration lung function increase morbidity . A recent Cochrane review conclude small benefit use prolong antibiotic treatment bronchiectasis , however randomize control trial adequate power standardize end point require . There report literature describe efficacy inhale tobramycin treatment patient non CF bronchiectasis eradication PA , significant improvement respiratory symptom . There however patient discontinue treatment due adverse event commonly cough wheeze dyspnea . ( Scheinberg Shore , Chest 2005 ) . TOBI Podhaler dry powder inhaler recently launch , much easy faster use compare nebulised Tobramycin . To best knowledge Tobramycin dry powder formulation yet trialed patient non CF bronchiectasis . The purpose trial ass efficacy tolerability TOBI Podhaler patient non CF bronchiectasis , gather data benefit continuous antibiotic therapy patient non CF bronchectais .</brief_summary>
	<brief_title>Efficacy &amp; Tolerability Tobramycin Podhaler Bronchiectasis Patients With Chronic Pseudomonas Aeruginosa Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>1 . Patients bronchiectasis confirm CT 2 . Chronic PA colonization 2 document sputum culture positive PA last 24 month . 3 . Age &gt; =18 1 . Patients diagnose CF 2 . Patients tolerate Tobramycin 3 . Pregnant breastfeed 4 . Patients treat last 8 week antibiotic therapy either inhaled systemic ( exclude Azenil PO x 3/week allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Tobramycin Podhaler</keyword>
	<keyword>bronchiectasis</keyword>
	<keyword>chronic infection</keyword>
	<keyword>Pseudomonas Aeruginosa</keyword>
</DOC>